Skip to Content

  • Search

View Additional Section Content

GOG-0170R – A Phase II Evaluation of Dalantercept (NSC #757172, IND# 116598), A Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of persistent or Recurrent Epithelial Ovarian, Fallopian tube or Primary Peritoneal Carcinoma

Clinical Trial Categories

  • Ovarian Cancer
Contact
Hanjani Institute for Gynecologic Oncology at 215-885-0220

Location

  • Hanjani Institute for Gynecologic Oncology
    The Rosenfeld Cancer Center
    1200 Old York Rd, AMH - 1 Widener
    Abington, PA 19001
    Office: 215-885-0220
    Fax: 215-576-0740

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a Test
Request an Appointment

215-481-EXAM

Clinical Trials Details